ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In line with the observation of Tanabe et al. (2020), where in CML BM-MKs correlated with BCR::ABL1 copy number after TKI treatment, we could speculate that the persistence of this MK population might represent an obstacle for the success of TFR.